Patents
Elekta aims to provide the highest level of cancer treatment possible, which means combining the most advanced technology with the most effective treatment techniques. In addition to working with industry and academic leaders through collaborative sponsored research programs, Elekta has its own extensive research and development program, which has resulted in a patent portfolio covering many important innovations in cancer care.
In accordance with Section 287(a) of Title 35 of the United States Code, and Section 15 of the UK#s Intellectual Property Act 2014, the reader is hereby placed on notice of Elekta's intellectual property rights for the following products protected by granted patents in the United States and the United Kingdom.
Agility™
- US 8,090,076
- US 8,467,499
- US 8,938,051
- US 9,737,732
- GB 2,423,909 B
- EP 2,153,448 B1
- EP 2,085,117 B1
- EP 2,285,447 B1
- EP 2,280,764 B1
Beam Modulator™
- US 6,711,237
Clarity®
- US 7,535,411
- US 7,634,304
- US 7,662,097
- US 7,672,705
- US 7,729,744
- US 8,000,442
- US 8,135,198
- US 8,189,738
- US 8,199,981
- US 8,249,317
- US 8,929,621
- US 9,248,316
- US 9,451,928
- EP 1,304,960 B1
- EP 1,774,312 B1
- EP 1,778,351 B1
- EP 1,778,074 B1
- EP 1,871,232 B1
- EP 1,913,333 B1
- EP 2,036,037 B1
- EP 2,063,960 B1
- EP 2,175,931 B1
- EP 2,293,843 B1
Connexion™
- US 9,121,421
Elekta Axesse™
- US 6,842,502
- US 7,471,765
- US 7,961,843
- EP 2,010,287 B1
- GB 2,525,074 B
Elekta Infinity™
- US 7,961,843
- EP 2,010,287 B1
- US 6,842,502
- US 7,471,765
- GB 2,525,074 B
Elekta Synergy®
- US 6,842,502
- US 7,471,765
- US 7,961,843
- EP 2,010,287 B1
- GB 2,525,074 B
Extend™
- EP 2,186,489 B1
- EP 2,112,457 B1
- US 8,393,821 B2
- US 8,100,132 B2
- US 8,088,083 B2
iViewGT™
- EP 1,207,787 B1
Leksell Coordinate Frame G
- US 8,221,435 B2
- EP 1,503,689 B1
Leksell Gamma Knife® Icon™
- US 6,931,096 B2
- US 7,313,222 B2
- US 6,968,036 B2
- US 7,492,866 B2
- US 7,729,473 B2
- EP 1,540,668 B1
- EP 1,540,667 B1
- EP 1,761,307 B1
- EP 1,868,684 B1
- EP 2,326,390 B1
Leksell Gamma Knife® Perfexion™
- US 6,931,096 B2
- US 7,313,222 B2
- US 6,968,036 B2
- US 7,492,866 B2
- EP 1,540,668 B1
- EP 1,540,667 B1
- EP 1,761,307 B1
- EP 1,868,684 B1
Leksell GammaPlan®
- EP 2,069,016 B1
Leksell® Vantage™ Stereotactic System
- US 7,846,116
Monaco®
- US 6,249,594
- US 6,266,453
- US 6,512,942
- US 7,171,255
- US 7,187,800
- US 7,201,715
- US 7,438,645
- US 8,098,909
- US 8,265,356
- US 8,577,107
- US 8,731,258
- US 8,867,806
- US 9,122,950
- US 9,122,959
- US 9,367,958
- US 9,460,360
- US 9,539,441
- US 9,572,998
- US 9,656,099
- US 9,764,162
- US 9,256,965
- US 9,629,598
- US 9,697,602
- US 9,740,710
- US 9,764,162
- US 9,652,871
- US 9,878,177
- US 9,974,977
- US 9,947,102
- US 9,965,863
Symmetry™
- US 7,356,112
- EP 1,589,876 B1
Versa HD™
- US 7,961,843
- EP 2,010,287 B1
- US 6,842,502
- US 7,471,765
- US 8,090,076
- US 8,467,499
- US 8,938,051
- US 9,737,732
- GB 2,423,909 B
- GB 2,525,074 B
- EP 2,153,448 B1
- EP 2,085,117 B1
- EP 2,285,447 B1
- EP 2,280,764 B1
XVI
- US 6,842,502
- US 7,471,765
- US 8,331,526
- US 7,796,728
- US 8,218,718
- EP 2,147,410 B1
- EP 1,796,543 B1
XVI 5.0.1
- US 9,271,684 B2
- EP 2,670,308 B1
Patent licensing
Elekta aims to provide the highest level of cancer treatment possible, which means combining the most advanced technology with the most effective treatment techniques. In addition to working with industry and academic leaders through research programmes, Elekta also acquires mature technology which has been proven to increase treatment accuracy, enhance the patient experience or improve treatment outcomes.
Elekta understands the importance of intellectual property and the role it plays in encouraging innovation and entrepreneurialism, having an extensive patent portfolio which covers many of the most important innovations in cancer care of the last four decades. However, we are always seeking new opportunities to augment our product range and intellectual property portfolio.
If you have a patented or patent pending cancer treatment technology or system that you think Elekta might be interested in, we want to hear from you. Please send your inquiry along with any additional information and contact details by completing the form below: